We’re not just securing email and e-signing.

We’re helping Amgen solve the next health challenges, by brining new biotech innovation to you faster.

And we’ve been with them since 2013.

RMail. For Life Sciences. Biotech.

  • Industry

Life Sciences

  • Sector


  • Geography

United States, Europe

  • Platform


Primary Use

Registered Email™ e-delivery proof

Watch full video of Branden Haines discuss RMail at Optimize!2020.

opening quote

The RMail and RSign feedback has been great. Everyone wants to use these products. The senior-level attorneys are always going to use RPost if they send anything out…The fact that RMail is going to be integrated with cleanDocs is going to encourage more use.

closing quote
Branden Haines, CTO at Dickinson Law

Branden Haines

CTO, Dickinson Law

Main Benefit

Timestamped proof of delivery of electronic physician packages and disclosures, reducing need for expensive courier, uncertain standard email, and eliminating paper.

Amgen enhanced its electronic clinical research system with RMail secure electronic messaging.

Amgen, an American multinational biopharmaceutical company headquartered in California, integrated RMail so that certain physician packages could be transmitted via Registered Email™ services with encryption when needed; importantly returning proof of delivery of disclosures to reduce risk. With RMail’s easy-to-use, cost-effective and award winning Registered Email™ service, Amgen was able to transmit essential documentation with returned delivery evidence, thereby complying with requirements.


Sending application automatically converts outbound messages of a certain type to Registered Email™ messages, transmitting via SMTP re-routing to RMail global networks, and receiving the analysis and delivery forensics sealed to delivered content and timestamps; the Registered Receipt™ proof record.

Amgen is one of the world’s largest life sciences companies with specialty in biotechnology. We’ve been providing assurance that critical medical disclosure packages are reaching researchers and physicians, to reduce risk of a missed critical communication; and to provide auditable, timestamped proof of content successful deliverery.

Tradenames are owned by the named company. Service benefit is summary, not intended to be a case study.RPost technology is patented. RMail, RSign, and RPost are trademarks owned by RPost.